<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Suarez | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/hoseboard38/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/hoseboard38/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Suarez.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">af71011665bf37a11b06fadcb2cedfb3</guid>
				<title>Suarez posted an update: [This corrects the article doi [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41589/</link>
				<pubDate>Sat, 08 Feb 2025 09:47:31 -0800</pubDate>

									<content:encoded><![CDATA[<p>[This corrects the article doi 10.1590/S0004-2803.202000000-32].Suggestions are made on how to write papers on bibliometrics.A system called QUALIS was implemented in Brazil in 2009, intended to rank graduate programs from different subject areas and promote selected national journals. Since this system uses a complicated suit of criteria&hellip;<span class="activity-read-more" id="activity-read-more-41589"><a href="http://www.nationalboardinstitute.com/activity/p/41589/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">542efbb2acd45feeaa9f12bced702241</guid>
				<title>Suarez posted an update: Stigmatization represents a major barrier to treatment [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39829/</link>
				<pubDate>Thu, 06 Feb 2025 10:23:20 -0800</pubDate>

									<content:encoded><![CDATA[<p>Stigmatization represents a major barrier to treatment seeking across mental disorders. Despite this, stigma research on individual mental disorders remains in its infancy. Attention-deficit hyperactivity disorder (ADHD) in adults also represents an under-researched area-being far less studied than its child counterpart. This study examined the&hellip;<span class="activity-read-more" id="activity-read-more-39829"><a href="http://www.nationalboardinstitute.com/activity/p/39829/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d860f8e48218254b5b599d08252796c7</guid>
				<title>Suarez posted an update: aluate measures of magnitude, precision, and relevance are [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38155/</link>
				<pubDate>Tue, 04 Feb 2025 09:52:03 -0800</pubDate>

									<content:encoded><![CDATA[<p>aluate measures of magnitude, precision, and relevance are included in this article.</p>
<p> Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory&hellip;<span class="activity-read-more" id="activity-read-more-38155"><a href="http://www.nationalboardinstitute.com/activity/p/38155/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e826134c6bc99f268e312a6abbfcbed2</guid>
				<title>Suarez posted an update: The interaction between TTO and azoles was evaluated through [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36366/</link>
				<pubDate>Sun, 02 Feb 2025 09:54:16 -0800</pubDate>

									<content:encoded><![CDATA[<p>The interaction between TTO and azoles was evaluated through the checkerboard and isobologram methods. <a href="https://www.selleckchem.com/products/erastin.html" rel="nofollow ugc">Ferroptosis activator</a> The results demonstrated both the fungicide activity of TTO on T. rubrum and the synergism when it was used in combination with azoles. Therefore, this mixture may reduce the minimum effective dose of azole required and&hellip;<span class="activity-read-more" id="activity-read-more-36366"><a href="http://www.nationalboardinstitute.com/activity/p/36366/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">97a8997f4ecede7ec63b24b0ce0dbb60</guid>
				<title>Suarez posted an update: The overall 1-year and 3-year freedom from recurrent MR [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34580/</link>
				<pubDate>Fri, 31 Jan 2025 09:57:42 -0800</pubDate>

									<content:encoded><![CDATA[<p>The overall 1-year and 3-year freedom from recurrent MR rates were 94.3% and 65.3%, respectively, and a significant difference was found between the SA group and the non-SA group (93.8% and 93.8% </p>
<p> . 95.5% and 44.2%, P=0.035). In a subgroup analysis, this significant difference was only found in the small LA group (≤60 mm).</p>
<p> Our r&hellip;<span class="activity-read-more" id="activity-read-more-34580"><a href="http://www.nationalboardinstitute.com/activity/p/34580/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3767471cf386cbca138af16a4e2c5c85</guid>
				<title>Suarez posted an update: Oesophagectomy following induction chemoradiation therapy [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/33576/</link>
				<pubDate>Thu, 30 Jan 2025 09:50:42 -0800</pubDate>

									<content:encoded><![CDATA[<p>Oesophagectomy following induction chemoradiation therapy (CRT) is technically challenging. To date, little data exist to describe the feasibility of a robotic approach in this setting. <a href="https://www.selleckchem.com/products/l-selenomethionine.html" rel="nofollow ugc">L-SelenoMethionine order</a> In this study, we assessed national trends and outcomes of robotic oesophagectomy following induction CRT compared to the traditional open&hellip;<span class="activity-read-more" id="activity-read-more-33576"><a href="http://www.nationalboardinstitute.com/activity/p/33576/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">07b2f09eee2f1c6da7b6ab97577d2a4a</guid>
				<title>Suarez posted an update: Immunization with recombinant glycoprotein-based vaccines is [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/30019/</link>
				<pubDate>Tue, 28 Jan 2025 14:36:43 -0800</pubDate>

									<content:encoded><![CDATA[<p>Immunization with recombinant glycoprotein-based vaccines is a promising approach to induce protective immunity against viruses. However, the complex biosynthetic maturation requirements of these glycoproteins typically necessitate their production in mammalian cells to support their folding and post-translational modification. Despite these clear&hellip;<span class="activity-read-more" id="activity-read-more-30019"><a href="http://www.nationalboardinstitute.com/activity/p/30019/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e3f84df0e5f571242c0c2724a6b89201</guid>
				<title>Suarez became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29990/</link>
				<pubDate>Tue, 28 Jan 2025 14:33:24 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>